What is GlycoMimetics?
GlycoMimetics, Inc. is a biotechnology company dedicated to the discovery and development of glycomimetic drugs. Its primary focus is on creating therapeutic solutions for diseases with significant unmet medical needs in the United States. The company's lead product candidates include rivipansel, a pan-selectin antagonist currently in Phase III clinical trials for sickle cell disease, and GMI-1271, an E-selectin antagonist being developed for acute myeloid leukemia and other hematologic cancers. GlycoMimetics is also advancing GMI-1359, a drug candidate targeting E-selectin and CXCR4, alongside inhibitors for galectin-3 and galectin-9. The company's strategic collaborations, such as its research and development agreement with Pfizer Inc., highlight its commitment to advancing its pipeline. Founded in 2003 and headquartered in Rockville, GlycoMimetics has established a robust development program in the competitive biopharmaceutical landscape.
How much funding has GlycoMimetics raised?
GlycoMimetics has raised a total of $288.8M across 7 funding rounds:
Series A
$9.6M
Series B
$15.4M
Series C
$38M
Stock Offering
$57.4M
Corporate Investment
$20M
Stock Offering
$20M
Stock Offering
$128.4M
Series A (2004): $9.6M with participation from Anthem Capital Management, Novartis Venture Fund, Maryland Department of Business and Economic Development, Alliance Technology Ventures, New Enterprise Associates, and PTV Sciences
Series B (2006): $15.4M led by Anthem Capital Management, Novartis Venture Fund, Maryland Department of Business and Economic Development, Alliance Technology Ventures, New Enterprise Associates, and PTV Sciences
Series C (2009): $38M supported by Alliance Technology Ventures, New Enterprise Associates, Genzyme Ventures, Novartis Venture Fund, and Anthem Capital
Stock Issuance/Offering (2014): $57.4M featuring Undisclosed
Corporate Investment (2015): $20M backed by Pfizer Inc.
Stock Issuance/Offering (2016): $20M with participation from Undisclosed
Stock Issuance/Offering (2018): $128.4M led by Undisclosed
Key Investors in GlycoMimetics
Novartis Venture Fund
Novartis Venture Fund is a venture capital arm of Novartis, a global pharmaceutical giant. They specialize in investing in early-stage companies with innovative technologies and therapies, particularly in the life sciences and biotechnology sectors, aiming to foster advancements in healthcare.
New Enterprise Associates
New Enterprise Associates (NEA) is a prominent venture capital firm with a broad investment focus, including significant backing for biotechnology and healthcare companies. They are known for supporting companies from inception through growth stages, providing both capital and strategic guidance.
Alliance Technology Ventures
Alliance Technology Ventures (ATV) is a venture capital firm that actively invests in technology and life science companies. Their expertise lies in supporting early-stage ventures, offering strategic insights and financial backing to help portfolio companies achieve significant milestones in research, development, and market entry.
What's next for GlycoMimetics?
The substantial capital raised by GlycoMimetics, particularly the recent strategic investment, positions the company for accelerated development and potential commercialization of its innovative drug candidates. This financing is expected to fuel the advancement of its Phase III trials for rivipansel and further the clinical progression of GMI-1271 and GMI-1359. The company's focus on glycomimetic therapies suggests a strategic intent to target complex diseases where traditional treatments are insufficient. Future growth will likely involve navigating regulatory pathways, expanding clinical research, and potentially forging further strategic partnerships to maximize the therapeutic reach of its pipeline.
See full GlycoMimetics company page
